Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
Price : $35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Registrational; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 04 Apr 2014 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Register.
- 04 Apr 2014 New source identified and integrated (European Clinical Trials Register).